跳至主要内容

Chemical synthesized peptide drugs

 

Company Profile:

Medicilon's peptide synthesis research team is closely focused on the topic of peptide drug research and is committed to solving the core problems that limit the development and application of peptide drugs. To improve the downstream peptide drug signal transduction pathways and mechanisms of action to improve the system. Through multi-disciplinary cooperation and intersections in chemistry, biology, medicine, and pharmacy, outstanding achievements have been made in basic and applied research.

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Peptide-Synthesis-Service
Chemical synthesized peptide drugs

Peptide Synthesis Service:

  • Standard chemical peptide synthesis

  • Peptide modification

  • Peptide library

  • Recombinant polypeptide expression

  • Pharmaceutical peptide synthesis

  • Structural modification

  • Nuclear magnetic structure analysis

  • function test

Peptide custom synthesis, peptide solid phase synthesis, synthetic peptide, biosynthetic peptide, genetic chemical synthesis

The development of peptide and protein drugs by chemical synthesis methods has become an effective method widely adopted. Through liquid phase synthesis, solid phase synthesis, solid/liquid synthesis combination and fragment connection, etc., many peptide and protein drugs have been successfully developed.

Peptide synthesis is the process of synthesizing polypeptides in organic chemistry. Polypeptides are organic compounds that are connected by multiple amino acids through peptide bonds. In biology, the process of synthesizing long polypeptides (proteins) is called protein biosynthesis. The synthesis of peptides is a process in which carboxyl groups (or C-terminus) and amine groups (or N-terminus) are paired with each other. Due to the possibility of unexpected reactions, protecting groups are necessary. The process of chemical peptide synthesis begins at the C-terminus and ends at the N-terminus of the peptide, whereas protein biosynthesis starts from the N-terminus and ends at the C-terminus of the polypeptide.

Contact us: 021-58591500

Email: marketing@medicilon.com

Website: www.medicilon.com

Related Articles:

Chemistry service

Chemical FTE Service

Medicilon Drug Impurity Analysis Service

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...